RMAM
FOLD

Raab & Moskowitz Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Raab & Moskowitz Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,900
Closed -$18K – 270
2019
Q4 		$18K Buy
+1,900
New +$17.4K 0.01% 350
2018
Q4 		– Sell
-2,500
Closed -$30K – 276
2018
Q3 		$30K Buy
+2,500
New +$35K 0.01% 304

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Raab & Moskowitz Asset Management's FOLD Position: Q1 2020 in Review

Raab & Moskowitz Asset Management sold out of Amicus Therapeutics (FOLD) in Q1 2020, closing a stake of 1,900 shares — an estimated $18K sold.

Raab & Moskowitz Asset Management first reported a position in FOLD in Q3 2018 and held it in 2 quarters. The position peaked at $30K in Q3 2018. 203 funds tracked by Wall St. Rank hold FOLD as of Q1 2020.

  • Raab & Moskowitz Asset Management reported no remaining Amicus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Raab & Moskowitz Asset Management sold 1,900 Amicus Therapeutics shares in Q1 2020, an estimated $18K.
  • Raab & Moskowitz Asset Management first reported a position in Amicus Therapeutics in Q3 2018 and held it in 2 quarters.
  • Raab & Moskowitz Asset Management's Amicus Therapeutics position peaked at $30K in Q3 2018.
  • 203 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2020.

Based on Raab & Moskowitz Asset Management's 13F filing for Q1 2020, filed 14 May 2020.